VolitionRx Gets Green Light For Nucleosome-Based Colorectal Cancer Test
Executive Summary
Blood-based cancer diagnostics firm VolitionRx CE-marked a new colorectal cancer-screening test that has shown the potential to reduce unnecessary colonoscopies by up to 25% when combined with the fecal immunochemical test (FIT) score.